GLPwatch
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
NCT05285397 · Unknown status
Last updated 2026-05-28This clinical trial is testing whether the medication liraglutide helps people who have had repeat weight-loss surgeries lose weight.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 60 people Planned (estimated).
Who can join all sexes
Timeline Started 2022-03 · est. completion 2022-09
Where 1 site · Egypt
What this study is testing ClinicalTrials.gov NCT05285397 ↗
Description as written by the study sponsor.
Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.
Treatments tested
- Liraglutide Pen Injector [Saxenda] Drug
Subcutaneous injection of GLP-1 agonist
| Main thing measured | Percentage Total weight loss |
|---|---|
| Sponsor | General Committee of Teaching Hospitals and Institutes, Egypt |
| Conditions studied | Morbid Obesity |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05285397 ↗